Drug
Epoetin Alfa clinical trials
Also written Procrit, EPO and Erypo.
Keep track of what changes. Save the Epoetin Alfa studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
- EPO
- 14
Combined with it in one product
Studies by the year they started
190 studies that test it; most in 2003 (16)
| Year | Studies |
|---|---|
| 1990 | 2 |
| 1991 | 1 |
| 1993 | 1 |
| 1995 | 3 |
| 1996 | 3 |
| 1997 | 4 |
| 1998 | 3 |
| 1999 | 4 |
| 2000 | 6 |
| 2001 | 9 |
| 2002 | 11 |
| 2003 | 16 |
| 2004 | 15 |
| 2005 | 10 |
| 2006 | 14 |
| 2007 | 12 |
| 2008 | 9 |
| 2009 | 4 |
| 2010 | 4 |
| 2011 | 7 |
| 2012 | 8 |
| 2013 | 10 |
| 2014 | 4 |
| 2015 | 7 |
| 2016 | 5 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Anemia
- 62
Who runs them
Industry 120 · Other 95
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (56) · Ortho Biotech Products, L.P. (10) · National Cancer Institute (NCI) (8) · Azidus Brasil (6) · Ortho Pharmaceuticals (6) · Pfizer (5) · Sandoz (5) · M.D. Anderson Cancer Center (4)
Often tested with
Tested in the same studies.
EPOCH Regimen (6) · Rituximab (5) · Erythropoietin (5) · Darbepoetin alfa (4) · Filgrastim (3) · Paclitaxel (3) · Alemtuzumab (2) · Iron sucrose (2)
Studies
Open first, then newest update. How each study uses Epoetin Alfa is read from its arms, and is right about nine times in ten.
Testing it · 215
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Epoetin Alfa
- Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESARecruitingPhase 1/2Groupe Francophone des MyelodysplasiesNCT05181735Written as Eprex
- Effect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing DialysisNot yet recruitingNot applicableServices Hospital, LahoreNCT07755683Written as Epoetin Alfa (drug)
- Pharmacokinetics, Pharmacodynamics, and Safety of NANOKINE Compared With Eprex 4000 U in Healthy VolunteersNot yet recruitingPhase 1Nanogen Pharmaceutical Biotechnology Joint Stock CompanyNCT06919861Written as Erythropoietin alfa
- Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center HemodialysisNot yet recruitingPhase 3Geoff BlockNCT07565701Written as Epoetin alga (Epogen)/vadadustat
- EVR and EPO for Liver Transplant ToleranceRecruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT06832189Written as Epoetin alfa
- Probiotics Against Erythropoietin Resistance in Chronic Kidney Disease Patients.Not yet recruitingPhase 3Badr UniversityNCT07296146Written as EPO
- ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA PatientsRecruitingPhase 3Australian and New Zealand Intensive Care Research CentreNCT04588311Written as Epoetin Alfa 40000 UNT/ML
- PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag).RecruitingPhase 3Incepta Pharmaceuticals LtdNCT07025681Written as Erythropoietin alfa
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and AnemiaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT00843882Written as Epoetin Alfa
- A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDSActive, not recruitingPhase 3Groupe Francophone des MyelodysplasiesNCT03223961Written as EPREX
- EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV InfectionCompletedPhase 2National Cancer Institute (NCI)NCT00006436Written as EPOCH
- Optimized Erythropoietin (EPO) TreatmentCompletedPhase 2University of IowaNCT02075970Written as Epoetin Alpha
- Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)CompletedPhase 3University of WashingtonNCT01378273Written as Epo
- Treatment and Natural History Study of Lymphomatoid GranulomatosisCompletedPhase 2National Cancer Institute (NCI)NCT00001379Written as Rituxan and EPOCH
- Impact of Erythropoietin on Hematological Adaptations and Physical PerformanceCompletedPhase 4United States Army Research Institute of Environmental MedicineNCT05078138Written as Epoetin Alfa
- Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney DiseaseCompletedPhase 3Bio Sidus SANCT04036253Written as Erythropoietin alfa
- PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in NewbornsCompletedPhase 3University of SydneyNCT03079167Written as Epoetin Alfa
- Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)TerminatedPhase 3Ontario Clinical Oncology Group (OCOG)NCT00310232Written as Epoetin Alfa
- Erythropoietin in Premature Infants to Prevent EncephalopathyTerminatedPhase 2Children's Hospital of Fudan UniversityNCT02550054Written as Epo
See all 215 studies that test Epoetin Alfa →
Given in every arm · 8 — Epoetin Alfa is usual care beside what is tested
- A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT07463820Written as Epoetin Alfa
- Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled TrialRecruitingPhase 4Piotr CzempikNCT06670963Written as EPO
- A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)CompletedPhase 4Hoffmann-La RocheNCT00773513Written as Epoetin Alfa
- Cross Iron (Comparative Randomized Oral Versus Systemic IRON)CompletedNot applicableUniversity Hospital, MontpellierNCT02496377Written as Epoetin Alfa
- LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)TerminatedPhase 2Novartis PharmaceuticalsNCT01034657Written as Epoetin Alfa
- Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck CancerCompletedPhase 2Drexel University College of MedicineNCT01467115Written as Erythropoetin
- Effects of Exercise in Combination With Epoetin AlfaCompletedNot applicableUniversity of ArkansasNCT00577096Written as Epoetin Alfa
- Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)CompletedPhase 2Nordic MDS GroupNCT01048034Written as Erythropoetin
As the comparator · 38 — what is tested is compared with Epoetin Alfa
- A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood TransfusionsRecruitingPhase 3TakedaNCT07422480Written as Epoetin Alfa
- Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological MalignanciesNot yet recruitingPhase 2/3Nanfang Hospital, Southern Medical UniversityNCT07636486Written as Epoetin
- ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood TransfusionsActive, not recruitingPhase 3Bristol-Myers SquibbNCT05949684Written as Epoetin Alfa
- A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.CompletedPhase 3Hoffmann-La RocheNCT00560404Written as Epoetin alfa
- Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable DialysisCompletedPhase 3Astellas Pharma Europe B.V.NCT02278341Written as Epoetin alfa
- A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA NaïveActive, not recruitingPhase 3CelgeneNCT03682536Written as Epoetin alfa
- Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis PatientsCompletedPhase 3SandozNCT00666835Written as ERYPO®, Janssen-Cilag
- Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin AlfaCompletedPhase 2Akebia TherapeuticsNCT03799627Written as Epoetin Alfa
- Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance HemodialysisCompletedPhase 2FibroGenNCT01147666Written as Epoetin Alfa
- Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable DialysisCompletedPhase 3FibroGenNCT02273726Written as Epoetin Alfa
- Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis ParticipantsCompletedPhase 3FibroGenNCT02052310Written as Epoetin Alfa
- Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)CompletedPhase 2GlaxoSmithKlineNCT03029247Written as Epoetin alfa
- Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis PatientsStatus unknownPhase 4Second Xiangya Hospital of Central South UniversityNCT04134026Written as Epoetin Alfa
- Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating AgentsTerminatedPhase 2Akebia TherapeuticsNCT03140722Written as epoetin alfa
- Study on Single Administration and Dose Increment of Recombinant Human Serum Albumin/Erythrocyte Fusion Protein for InjectionCompletedPhase 1Tianjin SinoBiotech Ltd.NCT03786289Written as Recombinant erythropoietin injection (CHO cells)
- Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney DiseaseCompletedPhase 1Akebia TherapeuticsNCT03992066Written as Epoetin alfa
- Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for CancerCompletedPhase 3Jonsson Comprehensive Cancer CenterNCT00070382Written as epoetin alfa
- Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis PatientsCompletedPhase 3CinnagenNCT03408639Written as Eprex®
- Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.CompletedPhase 3AstraZenecaNCT02174731Written as Epoetin alfa
- To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)Status unknownPhase 3Dong-A ST Co., Ltd.NCT03521713Written as EPREX
Showing 20 of 38.
Codes
What other systems call Epoetin Alfa · ClinicalTrials.gg INT006545
- MeSH (NLM) D000068817Epoetin AlfaConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 64FS3BFH5WEPOETINConfirmed FDA, NLM, Wikidata
- Wikidata Q5383794epoetin alfaConfirmed FDA, NLM, Wikidata
- DrugBank DB00016One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068817 | Epoetin Alfa | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 64FS3BFH5W | EPOETIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5383794 | epoetin alfa | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB00016 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.